Annual report for Sun Pharmaceutical Industries Ltd. for FY-2018
25-05-2018
Board Meeting-Outcome of Committee Meeting
This is to inform you that the Committee of Directors (Allotment) of the Board of Directors of the Company at its meeting held today, allotted 1,314 (One Thousand Three Hundred and Fourteen) equity shares of Re. 1/- each, on exercise of stock options under the SUN Employee Stock Option Scheme - 2015.24-05-2018
Sun Pharma gets USFDA nod for prostate cancer drug
Sun Pharmaceutical Industries' subsidiary has received approval from the US health regulator for YONSA, used for the treatment of a form of prostate23-05-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to USFDA Approval of YONSA, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,23-05-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Family Investment Pvt Ltd19-05-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Sudhir Valia19-05-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to US launch of authorized generic for Welchol Tablets, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,17-05-2018
Exercise Of Option To Submit Consolidated Financial Results As Per Regulation 33(3)(B) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As required under Regulation 33(3)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company will be additionally submitting quarterly / year-to-date Consolidated financial results along with Standalone financial results during the financial year 2018-19. This is for your information and record.17-05-2018
Declining sale of key drug weighs on Sun Pharma, stock down 7% in 2 days
Sales of acne drug Absorica were down 26 per cent on a sequential basis in the March quarter15-05-2018
Declining sale of key drug weighs on Sun Pharma, stock down 7% in 2 days
Sales of acne drug Absorica were down 26 per cent on a sequential basis in the March quarter14-05-2018